Replies to post #857 on BioSante Pharmaceuticals, Inc. (BPAX)

[shankapotamus]

12/20/2011 Eli Lilly And Co. LLY Florbetapir F 18 injection (NDA) FDA panel review of Florbetapir for use in positron emission tomography imaging of beta-amyloid) aggregates in brain to help rule out Alzheimer's disease



-News

12/08/2011 Antares Pharma Inc. AIS Anturol Gel (NDA) FDA decision on Anturol Gel for overactive bladder



-News

12/03/2011 Incyte Corporation INCY Ruxolitinib (NDA) FDA decision on Ruxolitinib as a treatment for myelofibrosis



-News

11/27/2011 Transcept Pharmaceuticals, Inc. TSPT Intermezzo (NDA resubmission) FDA to decide on Intermezzo as sleep aid for middle of the night awakenings



-News

11/18/2011 Regeneron Pharmaceuticals REGN EYLEA (BLA) FDA decision on EYLEA for treating neovascular age-related macular degeneration (wet AMD)



-News

11/14/2011 biosante pharmaceuticals inc. BPAX Bio-T-Gel (NDA) FDA decision on Bio-T-Gel for treatment of male hypogonadism or low testosterone levels. -Drug Status





-News

11/14/2011 Teva Pharmaceutical Industries Limited TEVA Bio-T-Gel (NDA) FDA decision on Bio-T-Gel for treatment of male hypogonadism or low testosterone levels -Drug Status





-News

11/13/2011 INTELGENX TECHNOLOGS IGXT.OB CPI-300 (NDA) FDA decision on CPI-300 for treating depression

-Market Potential



-News

11/12/2011 pSivida Limited PSDV ILUVIEN (NDA resubmission) FDA decision on ILUVIEN for the treatment of diabetic macular edema -Drug Status





-News

10/28/2011 Pacira Pharmaceuticals, Inc. PCRX Exparel (Amended NDA) FDA decision on Exparel for postsurgical pain management

-Market Potential



-News

10/28/2011 Bristol-Myers Squibb Co. BMY Dapagliflozin (NDA) FDA decision on Dapagliflozin as a proposed treatment of adults with type 2 diabetes mellitus.
-Rival Drugs



-Approved in Other Countries